The Food and Drug Administration approved Nplate for patients with a disorder that causes the body to attack its own platelets, tiny components of blood that help with clotting.

Bayer’s experimental anticoagulant Xarelto, its biggest new drug hope, has been recommended for approval by the European Medicines Agency.